![gemini 2 trial gemini 2 trial](https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/2013/nejm_2013.369.issue-8/nejmoa1215739/20130816/images/img_medium/nejmoa1215739_t1.jpeg)
The drug also contracts the ciliary muscle, which may make the eye more myopic.
![gemini 2 trial gemini 2 trial](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/b77462c8-4da8-4e02-9168-8b4fb6a863bf/gr6_lrg.jpg)
The mechanism of action involves contraction of the iris sphincter muscle, which constricts the pupil to improve near and intermediate vision acuity while maintaining some pupillary responsiveness to light. Vuity (AGN-190584) is a cholinergic muscarinic agonist that stimulates muscarinic receptors in smooth muscles such as the iris sphincter and ciliary. Symptoms of presbyopia include blurred vision and/or feeling tired while reading or doing any activity that requires near vision, headaches and eye strain. In a non-presbyopic vision, the shape of the transparent lens behind the iris may change and concentrate light to the retina, which makes it easier to see closely placed objects, while in a presbyopic eye, the clear lens hardens and does not change shape as quickly, making it harder to concentrate on close objects. The disorder affects approximately 128 million adults in the US. It impairs the eye’s ability to concentrate on close objects. Presbyopia is a common and progressive eye disorder that develops gradually and affects adults aged about 40 years.
![gemini 2 trial gemini 2 trial](https://d3i71xaburhd42.cloudfront.net/ff59b80543e524a4f3127f4ee15bd1a2ecf85738/5-Figure2-1.png)
Regulatory approvals for VuityĪbbVie submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for investigational AGN-190584 (1.25% pilocarpine HCl ophthalmic solution) for the treatment of presbyopia in February 2021, while the approval was granted in October 2021. The drug is available as an isotonic, colourless, sterile ophthalmic solution containing 1.25% (12.5mg/ml) of pilocarpine hydrochloride.